8-K: Castle Biosciences Exceeds 2025 Revenue Guidance

Castle Biosciences reported strong fourth quarter and full-year 2025 results, exceeding revenue guidance with $344 million and significant growth in core test reports.

Summary

• Full-year 2025 revenue reached $344.2 million, a 4% increase over $332.1 million in 2024. Excluding DecisionDx-SCC and IDgenetix revenue, growth was 34%.
• Fourth quarter 2025 revenue was $87.0 million, a 1% increase over $86.3 million in the same period of 2024. Excluding DecisionDx-SCC and IDgenetix, revenue growth was 43%.
• Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 37% for the full year 2025 over 2024.
• DecisionDx-Melanoma test reports delivered in 2025 were 39,083, up from 36,008 in 2024.
• TissueCypher Barretts Esophagus test reports delivered in 2025 were 39,014, an 86% increase from 20,956 in 2024.
• The company reported a net loss of $24.2 million for 2025, compared to a net income of $18.2 million in 2024.
• Adjusted EBITDA for 2025 was $44.0 million, a decrease from $75.0 million in 2024.
• Cash, cash equivalents, and marketable investment securities totaled $299.5 million as of December 31, 2025.
• The limited access launch of AdvanceAD-Tx materially expanded the total addressable market.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report. While the company demonstrated strong top-line growth in core products and exceeded revenue guidance, the significant decline in profitability (net loss and Adjusted EBITDA) raises concerns about cost management and the impact of strategic shifts like the IDgenetix discontinuation and Medicare coverage changes.

Positives

• Exceeded 2025 full-year revenue guidance with $344.2 million.
• Core revenue drivers (DecisionDx-Melanoma, TissueCypher) total test reports increased 37% for full-year 2025 over 2024.
• TissueCypher Barretts Esophagus test reports grew 86% over 2024, demonstrating strong momentum.
• Limited access launch of AdvanceAD-Tx materially expanded the total addressable market in dermatology.
• Maintained a strong balance sheet with $299.5 million in cash, cash equivalents, and marketable investment securities as of December 31, 2025.
• An independent expert consensus paper endorsed the DecisionDx-Melanoma test, supporting its use in guiding management decisions.
• New data demonstrated the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy (SLNB) decision making and enhancing recurrence risk prediction.
• A new systematic review and meta-analysis confirmed TissueCypher's clinically validated risk stratification for patients with Barretts esophagus.
• Recognized by the Houston Chronicle as a Houston Top Workplace for the fifth consecutive year, earning three Culture Excellence awards.

Negatives

• Reported a net loss of $24.2 million for 2025, a significant decline from net income of $18.2 million in 2024.
• Adjusted EBITDA for 2025 decreased to $44.0 million from $75.0 million in 2024.
• GAAP Gross margin for 2025 was 69%, down from 79% in 2024, affected by the loss of revenues from DecisionDx-SCC and a one-time $20.1 million acceleration of amortization expense.
• Discontinued the IDgenetix test offering effective May 2025, leading to a sharp decrease in test reports (3,605 in 2025 vs. 17,151 in 2024).
• DecisionDx-SCC revenue and test report volume were affected by changes in Medicare coverage effective April 24, 2025, and a re-focus of commercial efforts.
• Net cash provided by operations slightly decreased to $64.3 million in 2025 from $64.9 million in 2024.

Risks

• Assumptions or expectations regarding reimbursement for products and subsequent coverage decisions.
• Estimated total addressable markets for products and product candidates and the related expenses, capital requirements, and potential needs for additional financing.
• Anticipated cost, timing, and success of product candidates.
• Plans to research, develop, and commercialize new tests.
• Ability to successfully integrate new businesses, assets, products, or technologies acquired through acquisitions.
• Effects of macroeconomic events and conditions, including inflation, monetary supply shifts, labor shortages, liquidity concerns at financial institutions, recession risks, supply chain disruptions, tariffs, outbreaks of contagious diseases, and geopolitical events (e.g., Middle East and Ukraine-Russia conflicts).
• Possibility that subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results discussed.
• Planned installation of additional equipment and supporting technology infrastructures and implementation of certain process efficiencies may not enable the company to increase the future scalability of the TissueCypher test.
• Possibility that actual application of tests may not provide the anticipated benefits to patients.
• Possibility that newer gastroenterology franchise may not contribute to the achievement of long-term financial targets as anticipated.

Future Outlook

The Company anticipates generating between $340-350 million in total revenue in 2026, indicating an expected flat to slight growth compared to 2025's $344.2 million.

Management Comments

• "We closed out an outstanding year with a strong fourth quarter, reflecting the strength of our innovative test portfolio, disciplined execution and the dedication of the entire Castle team who continue to deliver meaningful impact for patients and clinicians every day."
• "We exited 2025 with clear leadership across our core dermatologic and gastrointestinal franchises, highlighted by continued momentum in TissueCypher, which achieved 86% test report growth over 2024."
• "In 2025, we also delivered an important milestone with the limited access launch of AdvanceAD-Tx, which materially expanded our total addressable market and reinforced our commitment to providing clinical answers to dermatology clinicians and their patients."
• "As we look ahead to 2026 and beyond, we believe we are well positioned to continue delivering stockholder value and capitalize on our nearand long-term opportunities, supported by continued test adoption growth for our core tests, a robust pipeline and a strong balance sheet."

Industry Context

StockSavvy.ai notes that Castle Biosciences' focus on specialized genomic tests in dermatology and gastroenterology aligns with the broader trend in healthcare towards personalized medicine and precision diagnostics. The strong growth in core test volumes, particularly TissueCypher, suggests effective market penetration in niche areas, while the launch of AdvanceAD-Tx positions the company to capitalize on the significant atopic dermatitis market, a segment seeing increasing innovation in targeted therapies.

Comparison to Industry Standards

• The filing does not provide specific comparisons to direct competitors' financial results or project outcomes.
• The endorsement of DecisionDx-Melanoma by an independent expert consensus panel and the publication of new data for TissueCypher and DecisionDx-UM in peer-reviewed journals (e.g., Journal of Clinical Gastroenterology, Nature Communications, Journal of the American Academy of Dermatology) indicate a commitment to rigorous scientific validation, which is a critical benchmark for credibility and adoption in the diagnostics industry.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through continued test adoption and pipeline development, but current profitability decline may impact short-term sentiment and share price.
• Patients/Clinicians: Benefit from innovative tests guiding care, improved risk assessment, and new treatment decision-making tools like AdvanceAD-Tx, enhancing patient outcomes.
• Employees: Recognition as a "Houston Top Workplace" and Culture Excellence awards indicate a positive internal environment and commitment to employee well-being and development.
• Creditors: A strong cash position of $299.5 million provides financial stability and liquidity.

Next Steps

• Continue driving test adoption growth for core tests.
• Further develop a robust pipeline of innovative tests.
• Capitalize on nearand long-term market opportunities.
• Execute the planned commercial rollout of AdvanceAD-Tx.
• Hold a conference call and webcast on February 26, 2026, to discuss results and provide a corporate update.

Key Dates

Recommendation

While Castle Biosciences demonstrated strong growth in core test volumes and exceeded revenue guidance, the significant decline in net income to a loss and a substantial drop in Adjusted EBITDA warrant caution. The company's strategic focus on new tests and pipeline development is promising, but investors should monitor the path to renewed profitability and the impact of Medicare coverage changes on key products. A 'hold' recommendation allows for observation of how these factors evolve in 2026.

Keywords

Castle Biosciences, CSTL, financial results, Q4 2025, full-year 2025, earnings report, DecisionDx-Melanoma, TissueCypher, AdvanceAD-Tx, dermatology, gastroenterology, molecular diagnostics, gene expression profiling, skin cancer, Barretts esophagus, atopic dermatitis, uveal melanoma, genomic tests, biotechnology, healthcare diagnostics, revenue, net loss, EBITDA, test reports, Medicare coverage, clinical validation, risk stratification, patient care